Brittany Barber

Brittany Barber

Auto-generated profile, based on publicly available information

Brittany Barber

Department of Otolaryngology‐Head and Neck Surgery University of Washington Seattle Washington USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2021 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
RHRouba Hadi
Rouba Hadi
HXHaodong Xu
Haodong Xu
BBBrittany R. Barber
Brittany R. Barber
MSMichi M Shinohara
Michi M Shinohara
Ata Saba MoshiriAta Saba Moshiri
Ata Saba Moshiri

1 September 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
JHJeffrey Harris
Jeffrey Harris
HAHani Almarzouki
Hani Almarzouki
BBBrittany Barber
Brittany Barber
RSRufus Scrimger
Rufus Scrimger
JRJacques Romney
Jacques Romney
HSHadi Seikaly
Hadi Seikaly

1 October 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NUNatalie F. Uy
Natalie F. Uy
KNKevin Ng
Kevin Ng
JVJenna M. Voutsinas
Jenna M. Voutsinas
VWVicky Wu
Vicky Wu
NFNeal D. Futran
Neal D. Futran
CRCristina P. Rodriguez
Cristina P. Rodriguez
296 Background: Immune checkpoint inhibitors (ICI) are approved for recurrent and/or metastatic squamous head and neck cancers (R/M HNSCC). Landmark trials have shown stable or improved patient (pt) reported quality of life outcomes. It is unclear how these translate into gastrostomy (G) and tracheostomy (T) dependence, opioid use, or ER/unplanned hospitalizations (UH) in an unselected population. We sought to explore these in our large single institution cohort. Methods: We reviewed R/M HNSCC pts receiving ICI at a tertiary referral NCI designated cancer center. Outcomes were assessed between the first dose of ICI and 100 days after the last dose of ICI. Overall survival (OS) was estimated via Kaplan-Meier estimation. Differences between groups were assessed via log-rank testing procedure and adjusted for age, tumor characteristics, and smoking status. Results: Between 1/2012 and 12/2019, we treated 152 pts with ICI, mostly male (n = 142, 82%), partnered/married (n = 103, 68%), with median age 64 years (range 23 – 90). The most common primary sites were oropharynx (n = 55, 36%) and oral cavity (n = 33, 22%). 50 (35%) had ≥2 lines of prior systemic therapy and 29 (19%) had an ECOG ≥2. The most common pt races were white (n = 114, 75%), Asian (n = 14, 9%), and Hispanic, any race (n = 6, 4%). 83 (55%) and 23 (15%) had history of smoking and heavy alcohol use respectively. Median duration of ICI therapy was 95 days (range 1-1720). Prior to ICI, 49 (32%) had G, 17 (11%) had T, and 15 (10%) had both. While on ICI, 6 (4%) had G placed, and 1 (1%) had a G removed; 1 (1%) had T placed, and 2 (1%) had T removed. 69 (45%) had ER visits and 57 (38%) had UH; 11 (7%) were directly related to ICI adverse effects. Prior to ICI, 104 (68%) were on opiates; requirements increased in 58 (41%) pts and decreased in 17 (12%) pts. Pre-existing G prior to ICI had worse OS on log-rank testing, but significance was lost when adjusted for variables. Pre-existing T prior to ICI (p = 0.001, HR 3.08, 95% Cl [1.56,6.08]), and pts with increasing opiate requirements on ICI (p value = 0.0007, HR 2.13, 95% Cl [1.38,3.28]) had worse OS. Conclusions: In our cohort, ICI did not change G or T usage. Pre-existing T and increasing opiate use were also associated with worse survival. Our data supports augmentation of palliative care and advanced care planning in the R/M HNSCC population.

13 May 2026 in Head & Neck
Verified
Journal Article
Open access
MUMateo Useche
Mateo Useche
LGLuis Gomez‐Castillo
Luis Gomez‐Castillo
KCKara Cushing‐Haugen
Kara Cushing‐Haugen
RFRocco Ferrandino
Rocco Ferrandino
NFNeal Futran
Neal Futran
BBBrittany Barber
Brittany Barber
Introduction: Oral cavity cancer (OCC) incidence is rising among non‐smokers and younger individuals without traditional risk factors. While carcinogenic exposures such as tobacco and alcohol are well studied, the association between unhealthy dietary patterns and OCC has been minimally explored. This study evaluated the association between dietary patterns and OCC risk in men and women. Methods: This prospective cohort study used data from three large U.S. longitudinal cohorts: the Nurses' Health Study ( n = 68 715, 1986–2016), Nurses' Health Study II ( n = 93 887, 1991–2017), and the Health Professionals Follow‐up Study ( n = 47 923, 1986–2016). Participants included 162 602 women and 47 923 men without cancer at baseline. Dietary intake was assessed every 4 years using validated food frequency questionnaires. Three dietary patterns were evaluated: Western, Prudent, and the Alternative Healthy Eating Index‐2010 (AHEI). Cox proportional hazard models estimated hazard ratios and 95% confidence intervals (CIs). Results: Over 30 years of follow‐up, 226 incident OCC cases were identified (124 in women and 102 in men). Among women, lower adherence to the Prudent and AHEI dietary patterns had higher OCC risk (HR for lowest vs. highest quartile, HR 1.86, 95% CI 1.03–3.35, and HR 2.17, 95% CI 1.24–3.77, respectively). Among non‐ or light‐smoking and non‐ or light‐drinking women, low adherence to the Prudent diet significantly increased OCC risk (HR for lowest vs. highest quartile 2.94, 95% CI 1.06–8.10). No associations were observed in men. Formal tests for interaction by sex were not statistically significant. Conclusions: Low adherence to Prudent and AHEI dietary patterns was associated with a higher risk of OCC in women but not men that warrants further investigation in larger pooled studies.